17.30USD-1.13%Mkt Cap: 1.81B USDP/E: —Last update: 2026-05-26
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory condit…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap1.81B USD
Enterprise Value1.33B USD
Revenue (TTM)71.78M USD
Gross Profit-259.60M USD
Net Income (TTM)-264.46M USD
Revenue/Share0.7690 USD
Last Price17.30 USD
Fiscal Year EndNov 2025
MR QuarterFeb 2026
Employees317
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.12
PEG—
EV/EBITDA-4.33
EV/Revenue18.54
P/S25.25
P/B3.77
EPS (TTM)-3.17
EPS (Forward)-2.86
52W Range
8.19564% of range22.50
52W High22.50 USD
52W Low8.195 USD
Profitability
Gross Margin0.00%
Oper. Margin-1479.45%
EBITDA Margin0.00%
Profit Margin-314.90%
ROE-49.09%
ROA-38.43%
Growth
Revenue Growth-66.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-249.47M USD
CapEx (TTM)14.00M USD
FCF Margin-202.65%
FCF Yield-8.03%
Net Debt-482.08M USD
Net Debt/EBITDA1.57
Balance Sheet
Debt/Equity0.10
Current Ratio6.01
Quick Ratio5.89
Book Value/Sh4.651 USD
Cash/Share5.229 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)30.18 USD
Target Range23.00 USD – 41.00 USD
# Analysts17
Ownership
Shares Out.103.41M
Float82.40M
Insiders1.09%
Institutions114.93%
Short Interest
Short Ratio17.5d
Short % Float18.78%
Short % Out.18.57%
Shares Short19.20M
Short (prev mo.)18.13M
Technical
SMA 5016.01 (+8.1%)
SMA 20014.43 (+19.9%)
Beta1.88
S&P 52W Chg28.31%
Avg Vol (30d)983.79K
Avg Vol (10d)1.20M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—